Enrollment is underway in two phase 2 clinical trials for dry eye disease and presbyopia, according to press releases from Glaukos.
GLK-301, a topical cream containing pilocarpine designed to treat signs and symptoms of dry eye disease, will be evaluated in a multicenter, randomized, double-masked, placebo-controlled trial. One of three different dose levels of GLK-301 or placebo will be applied to the eyelids of approximately 200 patients with dry eye twice daily for 28 days, followed by a 14-day safety assessment period.
“We believe our iLution platform has the potential (Read more...)